Cooper Releases “Discovery2” Human Immune System Simulator

Big Pharma Software Modeling Service Simulates Human Trial Results in Advance

SAN FRANCISCO--()--Today at the BIO Convention for industry leaders in biotech and pharmaceuticals, Cooper Human Systems announced initial commercial availability of its second-generation human immune system modeling service “Discovery2.”

“The ability to foresee eventual trial results and abandon (lose early) and re-architect portions of pharma’s development pipeline should save the pharma industry decades of time and billions of dollars currently spent in failed clinical trial pipelines of complex immune system disorders”

The modeling service is designed to save Big Pharma billions of dollars in clinical trial expenditures by providing simulator-based advance predictions of the eventual results of combination drug therapies in humans.

Over the past few years, Cooper engineers, system dynamics modelers, and immunologists have expended more than thirty (30) person-years of development to advance the Discovery2 simulator’s capabilities. Discovery2 demonstrates and predicts the human efficacy of drug combinations and protocols aimed at curing complex diseases related to the human immune system. Specific focus is currently being given to HIV, some cancers, and neurological disorders. Pharma and university partners provide scientific advice in collaboration with Cooper immunologists and modelers to strengthen the model and improve predictive outcomes.

The Cooper Discovery2 simulator not only helps pharma partners predict winners, but just as importantly, assists in identifying losers: those compounds which will not succeed in human trials. Recently the results of 14 HIV trials were run against the Cooper Discovery2 simulator, and Cooper successfully predicted the outcome in 11 of the 14 therapy combinations.

“The ability to foresee eventual trial results and abandon (lose early) and re-architect portions of pharma’s development pipeline should save the pharma industry decades of time and billions of dollars currently spent in failed clinical trial pipelines of complex immune system disorders,” said John Stafford, CEO at Cooper. “We believe the Cooper Discovery2 service provides a truly breakout series of value-added benefits to pharma partners, including enormous cost savings, improved pipeline confidence, accelerated time to market, longer duration revenue streams, and scientific and competitive advantage. And we believe our small and growing team of experts are well-positioned to delight pharma CFOs, business development personnel, and chief scientific personnel with high-quality commercial and scientific engagements.”

Cooper, in partnership with the Thai Red Cross AIDS Research Centre, initiated a phase I/II HIV functional cure clinical trial using a novel combination of three FDA-approved drugs based on Discovery2 and bypassing the typically prerequisite animal trials. The results of that trial will be presented at the International Aids Society (IAS) in Durban, South Africa in July 2016.

For a personalized partnership discussion at BIO please contact John Stafford at 619-876-1521 or john.stafford@coopersd.com.

About Cooper Human Systems

Cooper Human Systems is a privately held system dynamics modeling company based in Cambridge, MA. Cooper is focused exclusively on accelerating the success of pharmaceutical combination therapies of the human immune system. www.cooperhumansystems.com.

Contacts

Cooper Human Systems
John Stafford, 619-876-1521
john.stafford@coopersd.com

Release Summary

Cooper Human Systems announces initial commercial availability of its second-generation Human Immune System modeling service “Discovery2.”

Cooper Human Systems